Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.5%. By the end of trading, Gilead rose $0.90 (1.2%) to $73.03 on heavy volume. Throughout the day, 18,851,160 shares of Gilead exchanged hands as compared to its average daily volume of 11,730,700 shares. The stock ranged in a price between $71.90-$74.30 after having opened the day at $72.60 as compared to the previous trading day's close of $72.13. Other companies within the Drugs industry that increased today were:

22nd Century Group



), up 19.7%,




), up 12.4%,

Galectin Therapeutics



), up 8.8% and




), up 8.5%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $110.9 billion and is part of the health care sector. Shares are down 4.0% year to date as of the close of trading on Monday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front,

Revance Therapeutics



), down 8.4%,

Inovio Pharmaceuticals



), down 8.0%,

Bacterin International Holdings



), down 7.6% and

CytRx Corporation



), down 7.5% , were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.